Marco Filetti

Pubblicazioni

Titolo	Pubblicato in	Anno
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%. A multicenter study with external validation	JOURNAL FOR IMMUNOTHERAPY OF CANCER	2020
Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG	THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY	2020
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: A multicenter study with external validation	JOURNAL FOR IMMUNOTHERAPY OF CANCER	2020
Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors. the multicenter FAMI-L1 study	ONCOIMMUNOLOGY	2020
KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden	ANNALS OF ONCOLOGY	2020
A simplified genomic profiling approach predicts outcome in metastatic colorectal cancer	CANCERS	2019
Impact of tumor site on the prognosis of small bowel adenocarcinoma	TUMORI	2019
Unexpected serious aplastic anemia from PD-1 inhibitors. beyond what we know	TUMORI	2019
Predictive biomarkers for checkpoint inhibitor-based immunotherapy: The Galectin-3 signature in NSCLCs	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	2019
Clinical and psychometric validation of the BreSAS questionnaire module for symptom assessment among breast cancer survivors	SUPPORTIVE CARE IN CANCER	2019
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: When overweight becomes favorable	JOURNAL FOR IMMUNOTHERAPY OF CANCER	2019
Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study	THE ONCOLOGIST	2019
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: When overweight becomes favorable	JOURNAL FOR IMMUNOTHERAPY OF CANCER	2019
Prophylactic use of antiemetics for prevention of opioid-induced nausea and vomiting: a survey about Italian physicians’ practice	SUPPORTIVE CARE IN CANCER	2019
Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients	CLINICAL LUNG CANCER	2019
CDKN2A/B gene loss and MDM2 alteration as a potential molecular signature for hyperprogressive disease in advanced NSCLC: A next-generation-sequencing approach	JOURNAL OF CLINICAL ONCOLOGY	2019
Refined karyotype-based prognostic stratification of chronic lymphocytic leukemia with a low- and very-low-risk genetic profile	LEUKEMIA	2018
Anti epidermal growth factor receptor therapy in small bowel adenocarcinoma	MEDICINE	2018
Effective treatment of a platinum-resistant cutaneous squamous cell carcinoma case by EGFR pathway inhibition	MOLECULAR AND CLINICAL ONCOLOGY	2018
Resolution of remitting seronegative symmetrical synovitis with pitting edema (RS3PE) during Nivolumab therapy for non-small cell lung cancer: a case report	SEMINARS IN ARTHRITIS AND RHEUMATISM	2018

Pubblicazioni

Progetti di Ricerca